Prediction of steroid-sparing agent use in childhood idiopathic nephrotic syndrome

被引:16
|
作者
Harambat, Jerome [1 ]
Godron, Astrid [1 ]
Ernould, Sandrine [1 ]
Rigothier, Claire [2 ]
Llanas, Brigitte [1 ]
Leroy, Sandrine [3 ,4 ]
机构
[1] Ctr Hosp Univ Bordeaux, Ctr Reference Malad Renales Rares Sud Ouest, Serv Pediat, F-33076 Bordeaux, France
[2] Ctr Hosp Univ Bordeaux, Ctr Reference Malad Renales Rares Sud Ouest, Serv Nephrol, F-33076 Bordeaux, France
[3] Univ Oxford, Ctr Stat Med, Oxford, England
[4] Inst Pasteur, Epidemiol Emerging Dis Unit, Paris, France
关键词
Idiopathic nephrotic syndrome; Steroids; Immunosuppressive therapy; Prediction model; INITIAL TREATMENT; CHILDREN; CYCLOSPORINE; DEPENDENCY; CYCLOPHOSPHAMIDE; PREDNISONE;
D O I
10.1007/s00467-012-2365-8
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
About half of children with steroid-sensitive idiopathic nephrotic syndrome (INS) will develop steroid dependency or a frequently relapsing course requiring steroid-sparing agents (SSA). Because of the adverse effects of prolonged steroid treatment, the early identification of children at high risk of requiring SSA may be a useful diagnostic tool to tailor the therapeutic strategy. The aim of this study was to identify predictors of the need for SSA and derive a predictive model. This was a retrospective hospital-based cohort study which included all children with steroid-responsive INS followed for at least 4.5 months. Cox regression modeling and decision curve analysis were performed. A total of 120 children (81 boys) with INS were included and followed up for a median time of 6.7 (range 0.4-24.1) years. Median age at diagnosis was 3.4 years. Seventy-two (60 %) children required a SSA after a median time of 10 months following initial diagnosis. Male children, age at disease onset, methylprednisolone pulse use, and time to achieve first remission were significantly associated with the outcome. Time to achieve remission only remained significant after adjustment: hazard ratio (HR) = 1.9 [95 % confidence interval (CI) 1.5-2.5] if considered as a continuous variable, and HR = 4.1 (95 % CI 1.9-8.6) when dichotomized using the 9-day threshold. The area under the receiver operating curve of the related predictive model was 0.81 (95 % CI 0.74-0.89), and the decision curve analysis demonstrated that this model performed better than any other strategy. Time to first remission is a strong predictor of the need for SSA in pediatric INS. Further prospective and impact studies are warranted to confirm the accuracy and benefit of our prediction model.
引用
收藏
页码:631 / 638
页数:8
相关论文
共 50 条
  • [21] Impact of steroids and steroid-sparing agents on quality of life in children with nephrotic syndrome
    Khullar, Shawn
    Banh, Tonny
    Vasilevska-Ristovska, Jovanka
    Chanchlani, Rahul
    Brooke, Josefina
    Licht, Christoph P. B.
    Reddon, Michele
    Radhakrishnan, Seetha
    Piekut, Monica
    Langlois, Valerie
    Aitken-Menezes, Kim
    Pearl, Rachel J.
    Hebert, Diane
    Noone, Damien
    Parekh, Rulan S.
    [J]. PEDIATRIC NEPHROLOGY, 2021, 36 (01) : 93 - 102
  • [22] Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children
    Biswanath Basu
    Binu George Babu
    T. K. S. Mahapatra
    [J]. Clinical and Experimental Nephrology, 2017, 21 : 143 - 151
  • [23] RITUXIMAB VESUS CYCLOPHOSPHAMIDE AS FIRST STEROID SPARING AGENT IN CHILDHOOD FREQUENTLY RELAPSING OR STEROID DEPENDENT NEPHROTIC SYNDROME
    Kari, Jameela
    Albanna, Amr
    Alhassan, Khalid
    Safdar, Osama
    Shalaby, Mohamed
    Bockenhauer, Detlef
    Ei-Desoky, Sherif
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 709 - 709
  • [24] Azathioprine as a steroid-sparing agent in radiation pneumonitis
    McCarthy, MJ
    Lillis, P
    Vukelja, SJ
    [J]. CHEST, 1996, 109 (05) : 1397 - 1400
  • [25] Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children
    Basu, Biswanath
    Babu, Binu George
    Mahapatra, T. K. S.
    [J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2017, 21 (01) : 143 - 151
  • [26] Etanercept as Steroid-Sparing Agent in Dermatomyositis Reply
    Amato, Anthony A.
    [J]. ANNALS OF NEUROLOGY, 2011, 70 (04) : 671 - 672
  • [27] Successful use of apremilast as a steroid-sparing agent in chronic actinic dermatitis
    Kaushik, Akanksha
    Narang, Tarun
    Handa, Sanjeev
    [J]. DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [28] Chlorambucil as a steroid-sparing agent in bullous pemphigoid
    Chave, TA
    Mortimer, NJ
    Shah, DS
    Hutchinson, PE
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2004, 151 (05) : 1107 - 1108
  • [29] Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis
    Nadiminti, U
    Arbiser, JL
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (02) : S17 - S19
  • [30] Should rituximab be administered before cyclophosphamide as a first-line steroid-sparing agent to young children with steroid-dependent nephrotic syndrome?
    Shuichiro Fujinaga
    Akira Mizutani
    [J]. Clinical and Experimental Nephrology, 2020, 24 : 1187 - 1188